Peptide
PT-141
PT-141 is used or studied for libido enhancement and related sexual wellness, pigmentation and cosmetic use goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
In depth
Relationship to bremelanotide
PT-141 is the research/development name for the same molecule marketed as the FDA-approved drug bremelanotide (brand name Vyleesi). It is a selective MC3R/MC4R melanocortin receptor agonist that acts in the hypothalamus to influence sexual desire directly, rather than affecting blood flow the way PDE5 inhibitors like sildenafil or tadalafil do.
The FDA-approved version is specifically indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, delivered by a single-use subcutaneous autoinjector — it is not approved for men or for postmenopausal women.
Safety and who should avoid it
The FDA label lists nausea, flushing, and headache as common effects, and advises caution in people with uncontrolled hypertension or known cardiovascular disease. It should not be combined with naltrexone. Formulations sold outside the approved autoinjector product carry additional uncertainty around dose accuracy and purity.
Detail
Overview
PT-141 is used or studied for libido enhancement and related sexual wellness, pigmentation and cosmetic use goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Benefits, side effects, and protocols
Benefits list
- Libido enhancement
Side effects
- Nausea
- flushing
Vendor protocol
- None listed
Clinical protocol
- None listed
Evidence
- High
- Same as bremelanotide
Regulatory
- Fda Approved
- Prescription required
Research
Mechanisms
Evidence notes
- High
- Same as bremelanotide
Administration
Research links
Contraindications
- None listed
Components
- None listed
Regulatory data
- Fda Approved
- Prescription required
Aliases
- None listed
Used in these stacks
Related compounds
Half-life
How long does PT-141 stay in your system?
Half-life ≈ 2.7 hours — see what remains after any number of days, and when it is practically cleared.
Terminology on this page
Concepts from the glossary that come up around PT-141.
Frequently asked questions
Is PT-141 the same as bremelanotide?
Yes — PT-141 and bremelanotide refer to the same active molecule. Bremelanotide is the approved drug name (brand name Vyleesi); PT-141 is the name commonly used in research and compounding contexts.
Is PT-141 FDA approved?
Yes, under the brand name Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not approved for men or for postmenopausal women.
How is PT-141 different from Viagra or Cialis?
PT-141 (bremelanotide) acts on melanocortin receptors in the central nervous system, while sildenafil and tadalafil act on blood flow through the PDE5/nitric oxide pathway. They are mechanistically unrelated.
What are the side effects of PT-141?
The FDA label lists nausea, flushing, and headache as the most common effects, with caution advised for people with uncontrolled hypertension or cardiovascular disease.
Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations. Sourcing PT-141? Check your source before you use anything.